MEENAKSHI ANURAG to Humans
This is a "connection" page, showing publications MEENAKSHI ANURAG has written about Humans.
Connection Strength
0.192
-
How valuable can proteogenomics be in clinical breast cancer research? Expert Rev Proteomics. 2023 Jan-Mar; 20(1-3):1-4.
Score: 0.018
-
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer. Cancer Discov. 2022 11 02; 12(11):2586-2605.
Score: 0.017
-
Response to J?z?quel, Patsouris, Guette, et al. J Natl Cancer Inst. 2020 08 01; 112(8):865.
Score: 0.015
-
Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance). J Natl Cancer Inst. 2020 07 01; 112(7):737-746.
Score: 0.015
-
CDK4/6 Inhibitor Biomarker Research: Are We Barking Up the Wrong Tree? Clin Cancer Res. 2020 01 01; 26(1):3-5.
Score: 0.014
-
Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers. Clin Cancer Res. 2018 10 01; 24(19):4887-4899.
Score: 0.013
-
Location of disorder in coiled coil proteins is influenced by its biological role and subcellular localization: a GO-based study on human proteome. Mol Biosyst. 2012 Jan; 8(1):346-52.
Score: 0.008
-
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 Mar 01; 10(3):362-371.
Score: 0.005
-
The Breast Cancer Proteome and Precision Oncology. Cold Spring Harb Perspect Med. 2023 10 03; 13(10).
Score: 0.005
-
Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer. Cancer Res. 2023 10 02; 83(19):3237-3251.
Score: 0.005
-
Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins. Cancer Res Commun. 2023 08; 3(8):1551-1563.
Score: 0.005
-
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment. Cancer Res Commun. 2023 07; 3(7):1366-1377.
Score: 0.005
-
Personalized ctDNA micro-panels can monitor and predict clinical outcomes for patients with triple-negative breast cancer. Sci Rep. 2022 10 22; 12(1):17732.
Score: 0.004
-
Elevated NRAS expression during DCIS is a potential driver for progression to basal-like properties and local invasiveness. Breast Cancer Res. 2022 10 18; 24(1):68.
Score: 0.004
-
Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer. Cancer Res. 2022 08 16; 82(16):2928-2939.
Score: 0.004
-
Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031). Clin Cancer Res. 2022 08 02; 28(15):3287-3295.
Score: 0.004
-
Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer. Cancer Res. 2021 12 15; 81(24):6259-6272.
Score: 0.004
-
Immunogenomic?profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. Breast Cancer Res Treat. 2021 Aug; 189(1):187-202.
Score: 0.004
-
Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell. 2021 03 08; 39(3):361-379.e16.
Score: 0.004
-
Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. Cell. 2020 11 25; 183(5):1436-1456.e31.
Score: 0.004
-
Universal concept signature analysis: genome-wide quantification of new biological and pathological functions of genes and pathways. Brief Bioinform. 2020 09 25; 21(5):1717-1732.
Score: 0.004
-
Neurofibromin Is an Estrogen Receptor-a Transcriptional Co-repressor in Breast Cancer. Cancer Cell. 2020 03 16; 37(3):387-402.e7.
Score: 0.004
-
Microscaled proteogenomic methods for precision oncology. Nat Commun. 2020 Jan 27; 11(1):532.
Score: 0.004
-
Endocrine therapy resistance: new insights. Breast. 2019 Nov; 48 Suppl 1:S26-S30.
Score: 0.004
-
Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort. Breast Cancer Res Treat. 2020 Jan; 179(1):3-10.
Score: 0.003
-
Copy number alterations associated with clinical features in an underrepresented population with breast cancer. Mol Genet Genomic Med. 2019 07; 7(7):e00750.
Score: 0.003
-
The prognostic effects of somatic mutations in ER-positive breast cancer. Nat Commun. 2018 09 04; 9(1):3476.
Score: 0.003
-
Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Rep. 2018 08 07; 24(6):1434-1444.e7.
Score: 0.003
-
Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer. Cancer Discov. 2017 10; 7(10):1168-1183.
Score: 0.003
-
Amplification of TLK2 Induces Genomic Instability via Impairing the G2-M Checkpoint. Mol Cancer Res. 2016 10; 14(10):920-927.
Score: 0.003
-
Crowd sourcing a new paradigm for interactome driven drug target identification in Mycobacterium tuberculosis. PLoS One. 2012; 7(7):e39808.
Score: 0.002